Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Measuring and Mapping Cognitive Decline After Brain Radiosurgery

A legfontosabb adatok

Ki végzi
University of Nottingham
Hol
Egyesült Királyság1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
80 fő, tervezett
Kezdés
2024. jún. 21.
Befejezés
2026. jún. 30.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • Neurocognitive testing
  • Quality of Life questionnaire
  • Stereotactic radiosurgery
A regiszteradat frissítve
2026. május 4.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients will be eligible for inclusion only if ALL of the following criteria apply:
  • Age: above 18 years, no upper limit
  • Diagnosis of brain metastases or meningioma, where the treatment is going to be stereotactic radiosurgery
  • Karnofsky Performance Status (KPS) ≥70
  • Established diagnosis of cancer with absent or controllable primary disease
  • Tumour volume of less than 20cc
  • Life expectancy of more than 6 months
  • Able to give informed consent
  • Patients will be eligible for inclusion only if ALL of the following criteria apply:
  • Age: above 18 years, no upper limit
  • Diagnosis of meningioma
  • Previous SRS treatment at least 1 year prior to inclusion in the study
  • Most recent MRI scan (within 1 year) shows stable appearances
  • Able to give informed consent

Ki nem vehet részt

  • Previous RT to the brain, including SRS
  • Previous surgery to the brain
  • Previous RT to the brain, excluding SRS
  • Previous surgery to the brain
  • Not willing or not able to give informed consent
  • Not willing or not able to give informed consent

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Background Stereotactic Radiosurgery (SRS) is a localised radiotherapy treatment for patients with brain metastases or other benign tumours in the brain, like meningiomas. The Investigators do not currently know if, or how much, SRS affects brain function. Patients with brain tumours do not get tested routinely for their brain function.

A teljes eredeti leírásKevesebb

Understanding short- and long-term side-effects is important for SRS. Brain metastases patients have short life expectancies (6-months to 1-year). However, meningioma patients can live 10 years or more. SRS is used to treat both.

The Montreal Cognitive Assessment will be used to test the participants' brain function. Quality-of-life questionnaires QLQ-C30 and BN20 will also be used to assess the participants' physical and mental wellbeing . These are specific for patients with brain cancer.

Why is it important This study aims to identify areas in the brain that relate to changes in brain function after SRS. These areas can then have the radiation dose reduced to them in future patients, hoping to minimise side-effects.

Research Question Which regions of the brain contribute to a decline in brain function following SRS.

Study Design This is a single centre observational study with prospective and retrospective collection of data.

This study will look at two groups of patients:

Group1: Patients will complete the MoCA and two quality-of-life questionnaires before the treatment and every 3 months for a year.

Group2: Patients will complete the MoCA and two quality-of-life questionnaires once.

The investigators will use these tests, MRI scans and the SRS treatment plan to identify areas of the brain that are responsible for any problems with the participants' brain function.

The participants for Group 1 will be recruited from the SRS Clinics, at City Campus, Nottingham University Hospitals NHS Trust.

The participants for Group 2 will be identified through the Mosaiq Oncology Information System.

This pilot study is funded by the Midlands Mental Health and Neurosciences Network.

A vizsgálat 2 csoportja

  • Prospective

    Patients with brain metastases and meningiomas that are eligible for SRS treatment will be included in the prospective arm of the trial. The patients will have neurocognitive testing in the form of the Montreal Cognitive Assessment (MoCA) and will answer two Quality of Life questionnaires (QLQs) by EORTC QLQ-C30 and BN20). The baseline visit will happen before they start their SRS treatment. The patients will be seen an additional 4 times, at 3, 6, 9 and 12 months after radiotherapy treatment. During each visit they will complete the MoCA and the QLQs. During the first follow up appointment they will also be asked to think back to before they had the treatment and answer the QLQs based on that.

    Kezelés: Neurocognitive testing, Quality of Life questionnaire és Stereotactic radiosurgery

  • Retrospective

    Patients with meningiomas that have received SRS treatment more than a year ago will be included in the retrospective arm of the trial. The patients will have neurocognitive testing in the form of the Montreal Cognitive Assessment (MoCA) and will answer two Quality of Life questionnaires (QLQs) by EORTC QLQ-C30 and BN20) once. They will also be asked to think back to before they had the treatment and answer the QLQs based on that.

    Kezelés: Neurocognitive testing, Quality of Life questionnaire és Stereotactic radiosurgery

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Measuring and Mapping Cognitive Decline After Brain Radiosurgery: a Pilot Study
Publikációk
A regiszteradat frissítve
2026. május 4.